Approval Positions Roxadustat As Japan HIF-PHI Pioneer

The latest batch of product approvals in Japan positions Astellas’s roxadustat as the pioneer in the country’s potentially large HIF-PH inhibitor market in anemia, while Takeda and Meiji Seika see other important approvals and the first biosimilar teriparatide receives a nod.

ApproveOnKeyboard_1200x675
Roxadustat Among Key New Japan Approvals • Source: Shutterstock

Astellas Pharma Inc.'s novel oral anemia drug roxadustat has become the first in its class to be approved in Japan and looks set to reach this potentially large market ahead of multiple close rivals.

The inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) was approved as Evrenzo for the treatment of renal anemia associated with...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Japan

More from Focus On Asia